Silver Oak Securities Incorporated Decreases Position in Eli Lilly and Company (NYSE:LLY)

Silver Oak Securities Incorporated cut its holdings in Eli Lilly and Company (NYSE:LLY) by 14.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,441 shares of the company’s stock after selling 243 shares during the period. Silver Oak Securities Incorporated’s holdings in Eli Lilly and Company were worth $840,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its holdings in Eli Lilly and Company by 5.1% in the 3rd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 3,514 shares of the company’s stock valued at $1,887,000 after purchasing an additional 170 shares during the period. Lantz Financial LLC boosted its holdings in Eli Lilly and Company by 9.8% in the 3rd quarter. Lantz Financial LLC now owns 1,219 shares of the company’s stock valued at $655,000 after purchasing an additional 109 shares during the period. Covenant Partners LLC boosted its holdings in Eli Lilly and Company by 101.4% in the 3rd quarter. Covenant Partners LLC now owns 1,003 shares of the company’s stock valued at $539,000 after purchasing an additional 505 shares during the period. Bfsg LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at $564,000. Finally, Lake Street Financial LLC boosted its holdings in Eli Lilly and Company by 1.9% in the 3rd quarter. Lake Street Financial LLC now owns 7,740 shares of the company’s stock valued at $4,214,000 after purchasing an additional 147 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday, April 15th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Finally, Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $728.05.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $737.86 on Monday. The firm’s fifty day moving average price is $761.79 and its 200 day moving average price is $667.10. Eli Lilly and Company has a 1-year low of $392.26 and a 1-year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a market cap of $701.09 billion, a price-to-earnings ratio of 126.90, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm posted $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.